EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer
JE Dowell, JD Minna - Nature Clinical Practice Oncology, 2006 - nature.com
JE Dowell, JD Minna
Nature Clinical Practice Oncology, 2006•nature.comAlthough the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib can produce dramatic and durable tumor responses, not all patients with non-small-
cell lung cancer (NSCLC) benefit from these drugs. This Viewpoint discusses the molecular
correlates of response for these agents in patients with NSCLC.
erlotinib can produce dramatic and durable tumor responses, not all patients with non-small-
cell lung cancer (NSCLC) benefit from these drugs. This Viewpoint discusses the molecular
correlates of response for these agents in patients with NSCLC.
Although the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib can produce dramatic and durable tumor responses, not all patients with non-small-cell lung cancer (NSCLC) benefit from these drugs. This Viewpoint discusses the molecular correlates of response for these agents in patients with NSCLC.
nature.com